Clinical trials: NSCLC Stage II
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma, Non-Small-Cell Lung
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
- Trial name
- NCT03102242
- Testing
- Atezolizumab
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Alliance Foundation Trials, LLC.
Non Small Cell Lung Cancer, ROS1 Proto Oncogene
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation…
- Conditions
- Non Small Cell Lung Cancer, ROS1 Proto Oncogene, Crizotinib
- Trial name
- NCT01945021
- Testing
- Crizotinib
- Where
- 44 sites in China, Japan and 2 more
- Volunteers
- 129 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of…
- Trial name
- NCT01685060
- Testing
- LDK378
- Where
- 52 sites in United States, Canada and 10 more
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer NSCLC
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).
- Trial name
- NCT02879617
- Testing
- durvalumab
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Non Small Cell Lung Cancer, Lung Cancer
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy.
- Trial name
- FLT3 (NCT04491084)
- Testing
- FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Albert Einstein College of Medicine
Non-small Cell Lung Cancer
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
Primary goal of the study is to assess the overall survival of the addition of hypofractionated image guided radiotherapy concurrently with Docetaxel and cisplatin.
- Trial name
- SMART (NCT00887315)
- Testing
- Docetaxel and cisplatin, Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago
Non-Small Cell Lung Cancer
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.
- Trial name
- NCT01529112
- Testing
- Lenvatinib, BSC
- Where
- 50 sites in United States, Belgium and 5 more
- Volunteers
- 135 people
- Sponsor
- Eisai Inc.
Non-small Cell Lung Cancer
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of…
- Trial name
- CANOPY-N (NCT03968419)
- Testing
- Canakinumab, Pembrolizumab
- Where
- 29 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer
This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in…
- Trial name
- NCT00269152
- Testing
- pemetrexed, cisplatin, carboplatin
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with…
- Trial name
- NCT03285321
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Greg Durm, MD
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic body radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00087438
- Testing
- stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Trial name
- NCT00661193
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel
- Where
- 124 sites in United States
- Volunteers
- 59 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Phase II Study of ZD6474 in Advanced NSCLC
The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor.
- Trial name
- NCT00290537
- Testing
- ZD6474, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC Stage IV, NSCLC, Recurrent
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
This is a multicenter single arm phase II clinical trial. All eligible patients will receive: Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v.
- Trial name
- NCT03713944
- Testing
- Carboplatin, Pemetrexed, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nasser Hanna
Non-small Cell Lung Cancer
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
This study is a single institution Phase II single arm trial to assess the efficacy of the combination of pevonedistat plus docetaxel in patients with previously treated advanced NSCLC (non-small cell lung cancer).
- Trial name
- NCT03228186
- Testing
- Pevonedistat, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lung Cancer, Non-Small Cell
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects with advanced (Stage IIIB or IV) non-small…
- Trial name
- NCT00549328
- Testing
- Pazopanib (GW786034)
- Where
- 13 sites in United States
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC
Rationale: Surgery remains the standard of care for stage 1 (T1-2a N0)non-small cell lung cancer. Stereotactic body radiation therapy is a newer radiation treatment that gives fewer but higher and possibly more effective doses of…
- Trial name
- POSTILV (NCT01753414)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Surgery
- Where
- 4 sites in China
- Volunteers
- 44 people
- Sponsor
- Radiation Therapy Oncology Group
Carcinoma, Non-Small-Cell Lung
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days…
- Trial name
- NCT00266812
- Testing
- Temozolomide and radiotherapy, Whole brain radiotherapy
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute